<div id="readability-page-1"><p>In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on Erasca, with a price target of <span id="expert-recommendation-target">$23.00</span>. The company’s shares closed yesterday at $10.46.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Rama covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Travere Therapeutics, and Erasca. According to TipRanks, Rama has an average return of <span>23.7%</span> and a 52.03% success rate on recommended stocks. </p> <p>In addition to J.P. Morgan, Erasca also received a Buy from Mizuho Securities’s Joseph Catanzaro in a report issued on May 12. However, on the same day, Bank of America Securities reiterated a Sell rating on Erasca (NASDAQ: ERAS).</p></div>

ERAS

ARKG

<p>J.P. Morgan analyst Anupam Rama has maintained a Buy rating on Erasca (ERAS) with a price target of $23.00, while the stock closed at $10.46. Rama has an average return of 23.7% and a success rate of 52.03% on his recommendations. Mizuho Securities also issued a Buy rating for Erasca, but Bank of America Securities reiterated a Sell rating on the same day.</p>

Tip Ranks

Erasca

Ark Genomic Revolution ETF

iShares Global Healthcare

VG Health

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

iShares US Pharma

SPDR S&P Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

JPMorgan Chase

Sarepta Therap

Travere Therapeutics

Mizuho Financial

Mizuho Financial Group, Inc.

Bank of America

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

J.P. Morgan Keeps Their Buy Rating on Erasca (ERAS)